文献速递儿科与产科急症重症综合管理与镇静镇痛

促红细胞生成素对早产儿神经保护作用的随机试验

A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants.
PubMed 文献 · N Engl J Med · 2020-01-01
一句话结论对胎龄24周0天至27周6天的极早产儿,出生后24小时内开始大剂量促红细胞生成素治疗,至矫正胎龄32周,未降低2岁时严重神经发育障碍或死亡的风险。

这项多中心、随机、双盲试验纳入941例胎龄24周0天至27周6天的极早产儿,出生后24小时内随机接受促红细胞生成素或安慰剂。促红细胞生成素静脉给药1000 U/kg,每48小时一次,共6次,随后皮下注射维持剂量400 U/kg,每周3次,至矫正胎龄32周。符合方案分析纳入741例(促红细胞生成素组376例,安慰剂组365例),2岁时死亡或严重神经发育障碍发生率两组均为26%(97例 vs 94例;相对危险度1.03;95%CI 0.81至1.32;P=0.80),无显著差异。早产儿视网膜病变、颅内出血、脓毒症、坏死性小肠结肠炎、支气管肺发育不良、死亡及严重不良事件频率两组均无显著差异。

要点

  • 极早产儿(胎龄24周0天至27周6天)出生后24小时内开始大剂量促红细胞生成素,至矫正胎龄32周,2岁时死亡或严重神经发育障碍发生率26% vs 26%(RR 1.03;95%CI 0.81至1.32;P=0.80),无显著差异。
  • 促红细胞生成素组与安慰剂组在早产儿视网膜病变、颅内出血、脓毒症、坏死性小肠结肠炎、支气管肺发育不良、死亡及严重不良事件频率上均无显著差异。
  • 严重神经发育障碍定义为严重脑瘫或贝利婴幼儿发展量表第三版复合运动或复合认知评分低于70(低于均值2个标准差)。
  • 促红细胞生成素方案:静脉1000 U/kg每48小时一次共6次,随后皮下400 U/kg每周3次至矫正胎龄32周。
  • 该试验未显示大剂量促红细胞生成素对极早产儿2岁时严重神经发育障碍或死亡有保护作用。

适用人群与场景

  • 胎龄24周0天至27周6天的极早产儿,出生后24小时内纳入。

诊断标准与关键阈值

  • 严重神经发育障碍:严重脑瘫或贝利婴幼儿发展量表第三版复合运动或复合认知评分低于70(低于均值2个标准差,评分越高表现越好)。
  • 主要终点为矫正胎龄22至26个月时的死亡或严重神经发育障碍。

处置流程与药物剂量

  • 促红细胞生成素静脉给药1000 U/kg,每48小时一次,共6次。
  • 随后皮下注射维持剂量400 U/kg,每周3次,至矫正胎龄32周。
  • 安慰剂为静脉生理盐水后给予假注射。

研究设计与关键结果

  • 多中心、随机、双盲试验,941例极早产儿随机分组;符合方案疗效分析741例(促红细胞生成素组376例,安慰剂组365例)。
  • 2岁时死亡或严重神经发育障碍:促红细胞生成素组97例(26%)vs 安慰剂组94例(26%);相对危险度1.03;95%CI 0.81至1.32;P=0.80,无显著差异。
  • 早产儿视网膜病变、颅内出血、脓毒症、坏死性小肠结肠炎、支气管肺发育不良、死亡及严重不良事件频率两组均无显著差异。

证据类型、等级与局限

  • 随机、双盲、多中心试验(PENUT,ClinicalTrials.gov NCT01378273),由美国国家神经疾病与卒中研究所资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对胎龄24周0天至27周6天的极早产儿,出生后24小时内开始大剂量促红细胞生成素至矫正胎龄32周,未降低2岁时死亡或严重神经发育障碍风险。
  • 该人群中促红细胞生成素未增加早产儿视网膜病变、颅内出血、脓毒症、坏死性小肠结肠炎、支气管肺发育不良、死亡或严重不良事件频率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established.

METHODS: In this multicenter, randomized, double-blind trial of high-dose erythropoietin, we assigned 941 infants who were born at 24 weeks 0 days to 27 weeks 6 days of gestation to receive erythropoietin or placebo within 24 hours after birth. Erythropoietin was administered intravenously at a dose of 1000 U per kilogram of body weight every 48 hours for a total of six doses, followed by a maintenance dose of 400 U per kilogram three times per week by subcutaneous injection through 32 completed weeks of postmenstrual age. Placebo was administered as intravenous saline followed by sham injections. The primary outcome was death or severe neurodevelopmental impairment at 22 to 26 months of postmenstrual age. Severe neurodevelopmental impairment was defined as severe cerebral palsy or a composite motor or composite cognitive score of less than 70 (which corresponds to 2 SD below the mean, with higher scores indicating better performance) on the Bayley Scales of Infant and Toddler Development, third edition.

RESULTS: A total of 741 infants were included in the per-protocol efficacy analysis: 376 received erythropoietin and 365 received placebo. There was no significant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelopmental impairment at 2 years of age (97 children [26%] vs. 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P = 0.80). There were no significant differences between the groups in the rates of retinopathy of prematurity, intracranial hemorrhage, sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or death or in the frequency of serious adverse events.

CONCLUSIONS: High-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age. (Funded by the National Institute of Neurological Disorders and Stroke; PENUT ClinicalTrials.gov number, NCT01378273.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Juul SE, Comstock BA, Wadhawan R, et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. N Engl J Med. 2020. PMID: 31940698. doi:10.1056/NEJMoa1907423

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。